证券代码：300404 证券简称：博济医药 公告编号：2025-042 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于注 销部分股票期权的议案》。根据公司《2022 年股票期权激励计划（草案）》等 有关规定，公司 1 名激励对象因个人原因离职导致其不再具备激励资格，公司注 销其已授予但尚未行权的股票期权 13,440 份。具体内容详见公司于 2025 年 4 月 26 日在巨潮资讯网上披露的《关于注销部分股票期权的公告》（公告编号： 2025-030）。 经中国证券登记结算有限责任公司深圳分公司审核确认，公司上述股票期权 注销事宜已办理完成。本次注销的部分股票期权尚未行权，注销后不会对公司股 本造成影响。 特此公告。 博济医药科技股份有限公司董事会 博济医药科技股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销 2022 年股票期权激励计划中已授予但尚未行权的部分股票期 权数量为 13,4 ...

Group 1: ZTE Information - ZTE Information has approximately 7,000 active users for SnapDevelop and plans to release a paid commercial version in the future [1] - EazyDevelop, which focuses on rapid development using AI technology, will support MCP calls and is set to launch a free trial version [1] - Baidao Software has made breakthroughs in RISC-V firmware and is collaborating with major companies like Huawei and Lenovo [1] Group 2: Boji Pharmaceutical - Boji Pharmaceutical's new orders for 2024 are projected to be 1.515 billion yuan, a year-on-year increase of 30.07% [2] - The company aims for a revenue target of 682 million yuan for 2025, with a focus on clinical business and technology transfer services [2] - The company is exploring AI applications in clinical trial processes and has seen a 20% growth in traditional Chinese medicine CRO orders [2] Group 3: Kehua Data - Kehua Data's revenue for 2024 is expected to be 7.757 billion yuan, a decrease of 4.71% year-on-year, with a net profit of 315 million yuan [3] - The intelligent computing center business has seen a revenue increase of 14.07%, while the new energy business revenue has decreased by 15.98% [3] - The company plans to enhance its intelligent computing center business and has completed a convertible bond project for future funding [3] Group 4: Tongyu Communication - Tongyu Communication's growth in the first quarter is attributed to increased overseas revenue and contributions from satellite communication [4] - The company is focusing on R&D in satellite communication and 5G integrated antennas, achieving significant results [4] - Future plans include targeting high-end markets and leveraging overseas advantages to assist domestic satellite manufacturers [4]

Group 1: Company Performance and Orders - In 2024, the company expects to achieve approximately 1.515 billion CNY in new orders, representing a year-on-year growth of about 30.07% [2] - The company anticipates that the growth rate for new orders in the traditional Chinese medicine CRO sector will be around 20%, accounting for approximately 30% of total new orders in 2024 [3] - As of the end of 2024, the company has unrecognized revenue from contracts amounting to approximately 2.759 billion CNY, with an expected 682 million CNY to be recognized as revenue in 2025 [4] Group 2: Market Conditions and Competition - The CRO market remains highly competitive, with some smaller CRO companies facing operational difficulties, layoffs, or even liquidation, leading to an expected increase in industry concentration [3] - The company maintains a strong competitive advantage due to its established presence and resources in the CRO market [3] - The nuclear medicine CRO market is emerging, with few companies having relevant project experience, which positions the company favorably for future projects [8] Group 3: Profitability and Margins - The company expects the gross margin for clinical business to slightly decline due to ongoing market competition, while the gross margin for preclinical business remains stable [4] - Despite the anticipated decline in gross margin, the company is focused on reducing costs and believes that net profit margins will not decrease [4] Group 4: Future Plans and Innovations - The company plans to continue focusing on clinical services while also developing preclinical research and drug evaluation services, as well as contract development and manufacturing organization (CDMO) services [6] - There are ongoing discussions for the transfer of self-developed projects, with expectations to achieve significant milestones in 2025 [5] - The company is actively exploring AI applications in clinical trial design and data analysis, with plans to expand its use in clinical monitoring and preclinical compound screening [9]

Core Viewpoint - 博济医药's 2024 annual report indicates significant revenue growth, but also highlights notable quarterly fluctuations in performance metrics [1] Financial Performance - The company achieved total revenue of 742 million yuan, representing a year-on-year increase of 33.50% [1] - Net profit attributable to shareholders was 28.78 million yuan, up 18.23% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 19.30 million yuan, showing a substantial increase of 92.71% year-on-year [1] - However, there were quarterly declines, with total revenue rolling quarter-on-quarter down by 1.48%, net profit down by 35.47%, and net profit excluding non-recurring items down by 38.24% [1] Revenue Breakdown - Clinical research services revenue reached 597 million yuan, a significant increase of 44.12% year-on-year, with new contract value growing by 38.56% to 1.305 billion yuan [5] - Preclinical research services revenue was 84.32 million yuan, reflecting a growth of 7.70% year-on-year, with new contract value around 158 million yuan [6] - Other consulting services revenue decreased by 13.02% year-on-year to 42.22 million yuan, with new contract value approximately 5.2 million yuan [7] Business Segments - The company continues to lead in traditional areas such as liver disease, oncology, and endocrinology while making breakthroughs in emerging fields like immunology and gene therapy [5] - In the medical device sector, the company conducted nearly 80 clinical research services and 40 registration services, securing 13 Class III medical device registrations [5] - The company has established partnerships with over 900 clinical trial service organizations and signed strategic cooperation agreements with more than 40 institutions [5] R&D and Innovation - The company has received over 10 invention patents and is progressing well with multiple self-research projects [8] - The drug evaluation center successfully passed the GLP qualification re-examination and received the GLP certification [6] - AI technology is being utilized in the design of new target compounds to enhance research efficiency and accuracy [6]

Summary of Boji Pharmaceutical Conference Call Company Overview - **Company**: Boji Pharmaceutical - **Industry**: Contract Research Organization (CRO) in the pharmaceutical sector Key Financial Highlights - **2024 Revenue**: 930 million CNY, a year-on-year increase of 92.71% [2] - **New Contract Amount**: 1.515 billion CNY, up 38.12% year-on-year [2] - **Unrecognized Revenue**: Approximately 2.76 billion CNY in contracts yet to be recognized [2] - **Clinical Business Revenue**: Accounts for 80.51% of total revenue, with a 44% year-on-year increase [3] - **Gross Margin**: Overall gross margin decreased by 3 percentage points; clinical business gross margin down by 2.73 percentage points [2][4] - **2025 Q1 Revenue**: 139 million CNY, net profit of 3.9 million CNY, and non-recurring net profit of 1.7 million CNY, showing a decline year-on-year [2][4] Business Strategy and Market Position - **Growth Strategy**: Focus on securing more projects to maintain growth, with order growth expected to stay above 30% [5] - **Market Conditions**: Competitive pricing pressures exist, but the company aims to maintain gross margins and avoid significant price reductions [6][7] - **Industry Trends**: Anticipation of a rebound in demand for innovative drug projects, particularly in registration and preclinical areas [8] Operational Insights - **Employee Count**: Close to 1,400 employees as of the end of 2024 [2] - **2025 Revenue Target**: Aiming for 970 million to 1 billion CNY, with traditional Chinese medicine orders expected to account for about 30% [2][10] - **Clinical Pre-Business**: Expected to generate approximately 680 million CNY in revenue for 2025 [10] Challenges and Risks - **Industry Competition**: Some smaller CROs are facing difficulties, leading to market consolidation [9] - **Order Cancellations**: A few orders were canceled due to financing issues, but this is not widespread [21] Future Outlook - **Revenue Growth**: The company is optimistic about achieving revenue and order growth in 2025 despite current market challenges [28] - **M&A Strategy**: Plans to pursue acquisitions to strengthen capabilities in clinical research and related fields [18] - **AI Integration**: Actively exploring AI applications in clinical trials and preclinical research [26][27] Conclusion Boji Pharmaceutical is positioned for growth in a competitive CRO market, with a strong focus on innovative drug development and strategic project acquisition. Despite facing challenges, the company maintains a positive outlook for future revenue and operational efficiency.

证券代码：300404 证券简称：博济医药 公告编号：2025-039 博济医药科技股份有限公司 关于提请股东大会授权董事会办理以简易程序向特定 对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第五届董事会第十三次会议，审议通过了《关于提请股东大会授权董事会办理 以简易程序向特定对象发行股票的议案》。公司董事会同意提请股东大会授权董 事会办理以简易程序向特定对象发行融资总额不超过人民币 3 亿元且不超过最 近一年末净资产 20%的股票（以下简称"本次发行"）的相关事宜，授权期限为 自公司2024年年度股东大会审议通过之日起至2025年年度股东大会召开之日止。 本议案尚需提交股东大会审议，具体情况如下： 一、本次授权事宜的具体内容 1、确认公司是否符合以简易程序向特定对象发行股票的条件 5、限售期限 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司证券发行注册管理办法》等法律、法规、规范性文件以及《公司章程》的规 定，对公司实际情况 ...

经核查独立董事陈青、谢康、李华毅的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律法规及《公司章程》中对独立董事独立性的相关要求。 博济医药科技股份有限公司董事会 2025 年 4 月 24 日 1 博济医药科技股份有限公司 董事会对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等相关要求，并结合公司独立董事出具 的《独立董事独立性自查情况表》，博济医药科技股份有限公司（以下简称"公 司"）董事会就公司在任独立董事陈青、谢康、李华毅的独立性情况进行评估并 出具如下专项意见： ...

博济医药科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为博济医药科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年度任职期间严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及其他有关法律法规和《公司章程》《独 立董事工作细则》等公司相关的规定和要求，忠实履行独立董事的职责，充分发 挥独立董事的作用，勤勉尽责，维护了公司整体利益，维护了全体股东尤其是中 小股东的合法权益，较好地发挥了独立董事作用。现将履职情况报告如下： 一、基本情况 本人李华毅，男，中国国籍，无境外永久居留权，广东外语外贸大学经济学 学士，注册会计师。2001 年 9 月至 2008 年 6 月，历任安永华明会计师事务所广 州分所审计员、高级审计员、助理审计经理、审计经理；2008 年 6 月至 2010 年 10 月，任广东九丰集团有限公司财务副总监；2010 年 11 月至 2022 年 7 月，任 星河湾集团有限公司内审部总监；2019 年 6 月至 2020 年 9 月， ...

博济医药科技股份有限公司 2024 年度独立董事述职报告 一、基本情况 本人陈青，男，中国国籍，无境外永久居留权，澳门亚洲公开大学工商管理 硕士。2020 年 7 月至今担任公司独立董事，曾任北京天恒可持续发展研究所所 长、青岛健特生物投资股份有限公司董事长、合肥城建发展股份有限公司独立董 事，现任巨人慈善基金会副理事长、无锡健特药业有限公司执行董事、无锡健特 生物工程有限公司董事长兼总经理、珠海康奇有限公司经理兼执行董事、电连技 术股份有限公司独立董事、格方乐融科技（珠海）有限公司董事长。 在担任公司独立董事期间，本人未在公司担任除独立董事与专门委员会成员 以外的任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东 之间不存在妨碍本人进行独立客观判断的关系，不存在影响独立董事独立性的情 况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件及《公司章程》 《独立董事工作细则》中关于独立董事独立性的相关要求。 二、履职情况 （一） 出席董事会及股东大会情况 1 2024 年度，公司召开了 8 次董事会会议，3 次股东大 ...

第五届董事会 2025 年第一次独立董事专门会议意见 独立董事：陈青、谢康、李华毅 2025 年 4 月 24 日 1 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等相关法律法规以及《公司章程》、《独 立董事工作细则》等有关规定，博济医药科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 24 日召开了第五届董事会 2025 年第一次独立董事专门会议。独 立董事本着认真、负责的态度和独立判断的原则，对本次会议相关事项进行了认 真审核并发表如下意见： 一、 《关于确认 2024 年度日常关联交易及 2025 年度日常关联交易预计的 议案》 经审核，我们认为：2024 年度公司与关联方发生的日常关联交易系基于实 际市场情况和业务发展需求，属于正常的经营行为，不存在损害公司及全体股东 利益特别是中小股东利益的情形。公司 2025 年度日常关联交易预计是基于日常 经营业务发展的需要而产生，关联交易价格参照市场公允价格，由双方协商确定， 定价遵循公平、合理、公允的原则，不存在向关联方输送利益的情形，不存在损 害上市公司及全体股东利益的情形。因此 ...